Alpha-4 beta-2 neuronal nicotinic acetylcholine receptor (α4β2 nAChR) (α4β2 nAChR)

The alpha-4 beta-2 (α4β2) neuronal nicotinic acetylcholine receptor is a pentameric ligand-gated ion channel predominantly expressed in the central nervous system, where it modulates the release of various neurotransmitters, most notably dopamine in the mesolimbic pathway (UniProt: P43681, P17787). It is the most abundant high-affinity nicotinic receptor subtype in the human brain and plays a critical role in mediating the reinforcing effects of nicotine (PubMed: 10991997). Dysregulation of α4β2 signaling is implicated in several neurological and psychiatric conditions, including nicotine addiction, cognitive decline in Alzheimer's disease, and certain forms of epilepsy (StatPearls: NBK470212). Bupropion, a widely used antidepressant and smoking cessation aid, functions as a non-competitive antagonist at this receptor (PubChem: CID 444). By blocking the α4β2 receptor, bupropion reduces the dopaminergic reward associated with nicotine intake and alleviates withdrawal symptoms (PubMed: 10991997). This interaction makes the α4β2 receptor a primary therapeutic target for treating substance use disorders and mood-related pathologies. Furthermore, the receptor's involvement in cognitive processes makes it a focus for developing pro-cognitive agents in neurodegenerative research.

Other names

nAChR alpha-4 beta-2CHRNA4-CHRNB2 receptorNicotinic acetylcholine receptor alpha-4 beta-2 subtypeNeuronal acetylcholine receptor subunit alpha-4 and beta-2 complex

Bupropion acts as a non-competitive antagonist of the α4β2 nicotinic acetylcholine receptor, binding within the ion channel pore to inhibit cation flux even in the presence of agonists like nicotine (PubMed: 10991997).